PANews reported on October 16th that digital asset finance company Propanc Biopharma announced a strategic financing agreement with family office Hexstone Capital for up to $100 million. The financing will accelerate the biopharmaceutical company's clinical pipeline development and aims to grow its digital asset portfolio to $100 million or more within the next 12 months. Hexstone Capital has previously invested in several companies with digital asset portfolios, including BTC, ETH, SOL, and DOGE.